Bio-Techne

Bio-Techne

Price: 52.50

Company and Business Model

Bio-Techne Corporation operates in the healthcare sector, specializing in the development and manufacturing of biotechnology products and tools. Its core offerings include proteins, antibodies, and reagents used in research and clinical applications. Major business segments consist of Protein Sciences, Diagnostics, and Clinical Diagnostics, with primary revenue sources stemming from sales of research reagents and instruments. The company serves academic, pharmaceutical, and biotechnology markets.

Investment Profile

The investment profile of Bio-Techne is more aligned with balanced investors, given its moderate growth potential and dividend yield. The stock exhibits characteristics suitable for those seeking a mix of capital appreciation and income, though it carries a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, while liquidity remains moderate.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
0.71 OK
Revenue QoQ — quarter-over-quarter revenue growth
5.3%
EPS surprise
-3.6% in line
20d volatility
2.8% stable
Dividend yield
0.6% low last ex-date: 2026-05-18
FMP / FinFeed data updated: 2026-06-11
Reco: Hold Potential: 60 Risk: 59 Updated: 2026-06-11 05:35
How recommendation works
Why AI thinks so:
Weak momentum and high risk; hold for now.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-05 02:49 Sell Hold Mixed performance; cautious outlook due to volatility.
2026-05-30 02:52 Hold Sell Weak fundamentals and negative momentum raise concerns.
2026-05-08 15:11 Hold Weak fundamentals and negative momentum raise significant concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-05-14 20:21 RBC Capital Update — → 62 44.74
2026-05-07 12:07 Evercore ISI Target Lowered 54 → 50 49.265
2026-05-07 11:26 Stifel Nicolaus Target Lowered 65 → 50 47.405

Nothing yet